Literature DB >> 14990627

Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?

Jose Baselga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14990627     DOI： 10.1200/JCO.2004.12.903

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

1.  EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis.

Authors:  Peng Chen; Long Wang; Bing Liu; Hai-Zhong Zhang; Hong-Chen Liu; Zui Zou
Journal:  Eur J Clin Pharmacol       Date:  2011-01-05       Impact factor: 2.953

2.  Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.

Authors:  Brendan D Looyenga; Irene Cherni; Jeffrey P Mackeigan; Glen J Weiss
Journal:  Transl Oncol       Date:  2011-04-01       Impact factor: 4.243

Review 3.  Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer.

Authors:  James E Frampton; Stephanie E Easthope
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

5.  Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.

Authors:  J F de Groot; M R Gilbert; K Aldape; K R Hess; T A Hanna; S Ictech; M D Groves; C Conrad; H Colman; V K Puduvalli; V Levin; W K A Yung
Journal:  J Neurooncol       Date:  2008-06-26       Impact factor: 4.130

6.  Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo.

Authors:  Xin-Shuai Wang; Li Zhang; Xiaocen Li; De-Jiu Kong; Xiao-Chen Hu; Xue-Zhen Ding; Jun-Qiang Yang; Meng-Qi Zhao; Yixuan He; Kit S Lam; She-Gan Gao; Tzu-Yin Lin; Yuanpei Li
Journal:  Nanomedicine (Lond)       Date:  2018-06-06       Impact factor: 5.307

7.  A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study).

Authors:  J Stebbing; M Harrison; R Glynne-Jones; J Bridgewater; D Propper
Journal:  Br J Cancer       Date:  2008-02-05       Impact factor: 7.640

Review 8.  EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality.

Authors:  G Milano; J-P Spano; B Leyland-Jones
Journal:  Br J Cancer       Date:  2008-05-27       Impact factor: 7.640

9.  The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer.

Authors:  Jian-Wei Zhang; Yuan-Yuan Zhao; Ying Guo; Cong Xue; Zhi-Huang Hu; Yan Huang; Hong-Yun Zhao; Jing Zhang; Xuan Wu; Wen-Feng Fang; Yu-Xiang Ma; Li Zhang
Journal:  Chin J Cancer       Date:  2013-07-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.